Grunnleggende statistikk
| LEI | 549300124Y3MQI87PT35 |
| CIK | 1789731 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Swedish Orphan Biovitrum AB (publ) - Depositary Receipt (Common Stock)
SEC Filings (Chronological Order)
På denne siden finner du en fullstendig, kronologisk liste over SEC-arkiveringer, med unntak av eierskaps-arkiveringer som vi leverer andre steder.
| June 26, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Amendment No. 4 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) A Wholly Owned Indirect Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name |
|
| June 26, 2023 |
Stockholm, Sweden, 24 June, 2023 EX-99.(a)(5)(iv) Exhibit (a)(5)(iv) Press release Stockholm, Sweden, 24 June, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISD |
|
| June 26, 2023 |
Stockholm, Sweden, 26 June, 2023 EX-99.(a)(5)(v) Exhibit (a)(5)(v) Press release Stockholm, Sweden, 26 June, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDIC |
|
| June 13, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Amendment No. 3 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) A Wholly Owned Indirect Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name |
|
| June 9, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Amendment No. 2 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) A Wholly Owned Indirect Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name |
|
| June 2, 2023 |
SC TO-T/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO Amendment No. 1 TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) A Wholly Owned Indirect Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name |
|
| May 25, 2023 |
Form of Letter to Clients for use by Brokers, Dealers, etc Exhibit (a)(1)(v) Offer to Purchase for Cash All Outstanding Shares of Common Stock of CTI BIOPHARMA CORP. |
|
| May 25, 2023 |
Form of Letter of Transmittal Exhibit (a)(1)(ii) LETTER OF TRANSMITTAL to Tender Shares of Common Stock of CTI BIOPHARMA CORP. |
|
| May 25, 2023 |
SC TO-T UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) A Wholly Owned Indirect Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name of Filing Person— |
|
| May 25, 2023 |
Summary Advertisement Exhibit (a)(1)(vi) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). |
|
| May 25, 2023 |
Stockholm, Sweden, May 25, 2023 EX-99.(a)(5)(iii) Exhibit (a)(5)(iii) Press release Stockholm, Sweden, May 25, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURIS |
|
| May 25, 2023 |
Form of Notice of Guaranteed Delivery Exhibit (a)(1)(iii) NOTICE OF GUARANTEED DELIVERY to Tender Shares of Common Stock of CTI BIOPHARMA CORP. |
|
| May 25, 2023 |
Form of Letter to Brokers, Dealers, Commercial banks, Trust Companies and Other Exhibit (a)(1)(iv) Offer to Purchase for Cash All Outstanding Shares of Common Stock of CTI BIOPHARMA CORP. |
|
| May 25, 2023 |
Offer to Purchase Table of Contents Exhibit (a)(1)(i) Offer to Purchase for Cash All Outstanding Shares of Common Stock of CTI BIOPHARMA CORP. |
|
| May 25, 2023 |
EUR 800,000,000 EUR TERM LOAN AND MULTICURRENCY REVOLVING CREDIT FACILITIES EX-99.(b)(2) Exhibit (b)(2) CONFIDENTIAL To: Swedish Orphan Biovitrum AB (publ) (the “Company”) For the attention of Henrik Stenqvist and Erik Krohn 9 May 2023 EUR 800,000,000 EUR TERM LOAN AND MULTICURRENCY REVOLVING CREDIT FACILITIES We Bank of America Europe Designated Activity Company and Danske Bank A/S (together the underwriters, bookrunners and mandated lead arrangers and hereafter referred |
|
| May 25, 2023 |
SEK 8,000,000,000 EQUITY BRIDGE FACILITY EX-99.(b)(1) Exhibit (b)(1) CONFIDENTIAL To: Swedish Orphan Biovitrum AB (publ) (the “Company”) For the attention of Henrik Stenqvist and Erik Krohn 9 May 2023 SEK 8,000,000,000 EQUITY BRIDGE FACILITY We Bank of America Europe Designated Activity Company and Danske Bank A/S (together the underwriters, bookrunners and mandated lead arrangers and hereafter referred to as the “Banks” in such roles) a |
|
| May 25, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Schedule TO-T (Rule 14d-100) CTI BIOPHARMA CORP. |
|
| May 25, 2023 |
MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT EX-99.(d)(3) Exhibit (d)(3) MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT THIS MUTUAL CONFIDENTIAL DISCLOSURE AGREEMENT (“Agreement”) is entered into as of March 3, 2023 (the “Effective Date”), by and between CTI BioPharma Corp., a Delaware corporation having its principal place of business located at 3101 Western Avenue, Suite 800, Seattle, WA 98121, and its affiliates and subsidiaries, and Swedish Or |
|
| May 10, 2023 |
Stockholm, Sweden, 10 Maj, 2023 EX-99.1 Exhibit 99.1 Press release Stockholm, Sweden, 10 Maj, 2023 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDICTION. Sobi to |
|
| May 10, 2023 |
EX-99.2 10th May, 2023 Acquisition of CTI Biopharma Expanding Sobi’s position in rare haematology Exhibit 99.2 This presentation contains forward-looking statements by Sobi that involve risks and uncertainties and reflect Sobi’s judgment as of the date of this presentation. These forward-looking statements generally are identified by words such as “believe,” “project,” “expect,” “anticipate,” “est |
|
| May 10, 2023 |
SC TO-C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 CTI BIOPHARMA CORP. (Name of Subject Company (Issuer)) CLEOPATRA ACQUISITION CORP. (Name of Filing Person—Offeror) An Indirect Wholly Owned Subsidiary of SWEDISH ORPHAN BIOVITRUM AB (PUBL) (Name of Filing Person |
|
| August 10, 2020 |
SELB / Selecta Biosciences, Inc. / Swedish Orphan Biovitrum AB (publ) - SC 13G Passive Investment SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Selecta Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.0001 par value per shar |
|
| November 12, 2019 |
Stockholm, Sweden, 9 November 2019 Exhibit (a)(5)(D) PRESS RELEASE Stockholm, Sweden, 9 November 2019 Sobi successfully completes tender offer for all outstanding shares of Dova Pharmaceuticals Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that its indirect wholly owned subsidiary Dragonfly Acquisition Corp. |
|
| November 12, 2019 |
SWTUY / Swedish Orphan Biovitrum AB SC TO-T/A - - AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 2) DOVA PHARMACEUTICALS, INC. (Name of Subject Company) DRAGONFLY ACQUISITION CORP. (Offeror) A Wholly Owned Subsidiary of DRAGONFLY HOLDING CORP. (Parent of Offeror) And An Indirect Wholly Owned Su |
|
| November 12, 2019 |
Stockholm, Sweden, 12 November 2019 Exhibit (a)(5)(E) PRESS RELEASE Stockholm, Sweden, 12 November 2019 Sobi successfully completes acquisition of Dova Pharmaceuticals Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) and Dova Pharmaceuticals, Inc. |
|
| November 1, 2019 |
SWTUY / Swedish Orphan Biovitrum AB SC TO-T/A - - AMENDMENT NO. 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 (Amendment No. 1) DOVA PHARMACEUTICALS, INC. (Name of Subject Company) DRAGONFLY ACQUISITION CORP. (Offeror) A Wholly Owned Subsidiary of DRAGONFLY HOLDING CORP. (Parent of Offeror) And An Indirect Wholly Owned Su |
|
| October 11, 2019 |
Exhibit (a)(5)(C) PRESS RELEASE Stockholm, Sweden, 11 October 2019 Sobi commences tender offer for all outstanding shares of Dova Pharmaceuticals Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) announced today that it has commenced a tender offer through its indirect wholly owned subsidiary Dragonfly Acquisition Corp. |
|
| October 11, 2019 |
EX-99.(D)(4) 10 a2239851zex-99d4.htm EX-99.(D)(4) Exhibit (d)(4) EXECUTION VERSION TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of September 30, 2019, is by and among Swedish Orphan Biovitrum AB (publ), a Swedish public limited liability company (“Parent”), Dragonfly Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of |
|
| October 11, 2019 |
Exhibit (d)(5) STRICTLY CONFIDENTIAL August 19, 2019 CONFIDENTIAL Swedish Orphan Biovitrum AB (publ) Tomtebodavägen 23A SE-112 76 Stockholm Sweden Attn: Mr. |
|
| October 11, 2019 |
SWTUY / Swedish Orphan Biovitrum AB SC TO-T - - SC TO-T QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| October 11, 2019 |
EX-99.(D)(3) 9 a2239851zex-99d3.htm EX-99.(D)(3) Exhibit (d)(3) EXECUTION VERSION TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of September 30, 2019, is by and among Swedish Orphan Biovitrum AB (publ), a Swedish public limited liability company (“Parent”), Dragonfly Acquisition Corp., a Delaware corporation and an indirect wholly owned subsidiary of P |
|
| October 11, 2019 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(B) Letter of Transmittal to Tender Shares of Common Stock of DOVA PHARMACEUTICALS, INC. |
|
| October 11, 2019 |
Exhibit (a)(1)(c) Notice of Guaranteed Delivery for Offer to Purchase for Cash All Outstanding Shares of Common Stock of DOVA PHARMACEUTICALS, INC. |
|
| October 11, 2019 |
EX-99.(A)(1)(F) 7 a2239851zex-99a1f.htm EX-99.(A)(1)(F) Exhibit (a)(1)(F) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below), and the provisions herein are subject in their entirety to the provisions of the Offer (as defined below). The Offer is made solely by the Offer to Purchase, dated October 11, 2019, and the related Letter of Tr |
|
| October 11, 2019 |
QuickLinks - Click here to rapidly navigate through this document Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of Dova Pharmaceuticals, Inc. |
|
| October 11, 2019 |
Exhibit (a)(1)(E) Offer to Purchase for Cash All Outstanding Shares of Common Stock of DOVA PHARMACEUTICALS, INC. |
|
| October 11, 2019 |
Exhibit (a)(1)(D) Offer to Purchase for Cash All Outstanding Shares of Common Stock of DOVA PHARMACEUTICALS, INC. |
|
| October 1, 2019 |
Exhibit 99.1 The following presentation was made available to employees of Dova Pharmaceuticals, Inc.: Notice to Investors The tender offer for the outstanding shares of Dova Pharmaceuticals Inc. (“Dova”) common stock has not yet commenced. This presentation is being given to Dova’s employees for informational purposes only and such presentation is neither an offer to purchase nor a solicitation o |
|
| October 1, 2019 |
SWTUY / Swedish Orphan Biovitrum AB SC TO-C - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DOVA PHARMACEUTICALS, INC. (Name of Subject Company) DRAGONFLY ACQUISITION CORP. (Offeror) A Wholly Owned Subsidiary of DRAGONFLY HOLDING CORP. (Parent of Offeror) And An Indirect Wholly Owned Subsidiary of SWEDIS |
|
| September 30, 2019 |
Stockholm, Sweden, 30 September 2019 Exhibit 99.1 PRESS RELEASE Stockholm, Sweden, 30 September 2019 Sobi to acquire Dova Pharmaceuticals creating a global growth platform in haematology Swedish Orphan Biovitrum AB (publ) (Sobi™) (STO:SOBI) today announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) by means of a tender offer. The consideration consists of an upfront payment of USD 27.50 per share in ca |
|
| September 30, 2019 |
SWTUY / Swedish Orphan Biovitrum AB SC TO-C - - UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE TO Tender Offer Statement Pursuant to Section 14(d)(1) or 13(e)(1) of the Securities Exchange Act of 1934 DOVA PHARMACEUTICALS, INC. (Name of Subject Company) DRAGONFLY ACQUISITION CORP. (Offeror) A Wholly Owned Subsidiary of DRAGONFLY HOLDING CORP. (Parent of Offeror) And An Indirect Wholly Owned Subsidiary of SWEDIS |
